{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:15:06Z","timestamp":1788077706947,"version":"build-2784847793"},"reference-count":21,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background: Cholestatic liver injury (CLI) is a rapidly progressive liver disorder characterized by the accumulation of bile acids (BA). The therapeutic effects of current medicines used to treat CLI are unsatisfactory. Objectives: This study aimed to prepare galactosylated solid lipid nanoparticle (SLN) with swertiamarin (STM) by using a galactosylated lipid, N-hexadecyl lactobionamide (N-HLBA) and evaluate its anti-cholestasis effect in-vitro. Methods: The galactosyl-lipid N-HLBA was prepared via the lactone form intermediates of lactobionic acid and synthesized by anchoring galactose to hexadecylamine lipid. The STM-loaded galactosylated SLN (STM-GalSLN) was successfully prepared by a melt-emulsification-ultrasound method. The prescription was optimized by orthogonal test. The morphology was observed by transmission electron microscope. The particle size and zeta potential were determined by laser granularity equipment. The encapsulation efficiency (EE) and drug loading capacity (DL) were determined by ultrafiltration, centrifugation and HPLC method. Results: The optimized prescription was as follows: 50 mg of STM, 20 mg of N-HLBA, 500 mg of glyceryl behenate, 400 mg of soybean lecithin, 200 mg of poloxamer188 and 500 mg of Tween 80. The STM-GalSLN was spherical in shape and its particle size, zeta potential, EE and DL were 164.40\u00b14.68 nm, -14.53\u00b13.20 mV, 82.41\u00b12.88 % and 0.32\u00b10.02 %, respectively, and the EE of STM-GalSLN did not change significantly over 30 days at 4\u00b0C. Furthermore, STM-GalSLN alleviated cholestatic liver injury (CLI) in a concentration-dependent manner in-vitro. Conclusion: The findings from this study indicated that the melt-emulsification-ultrasound method was rational and reliable, which provided an experimental basis for developing a new nano preparation of STM for CLI.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.9.262.1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:02:34Z","timestamp":1782633754000},"source":"Crossref","is-referenced-by-count":0,"title":["Preparation, characterization and in-vitro anti-cholestatic activity of swertiamarin-loaded galactosylated solid lipid nanoparticle"],"prefix":"10.36721","author":[{"given":"Tao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Damayanti NI, Khong NMH, Liew CV and Chutoprapat R (2025). Surfactant ratio-driven modulation of caffeine loading and release in nigella sativa oil nanostructured lipid carriers. ACS Omega, 10(47): 57306-57314.","DOI":"10.1021\/acsomega.5c07460"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Fathi F, Machado TOX, de ACKH, Portugal I, Ferreira IO, Zielinska A, Oliveira M and Souto EB (2024). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the delivery of bioactives sourced from plants: Part I - composition and production methods. Expert Opin Drug Deliv, 21(10): 1479-1490.","DOI":"10.1080\/17425247.2024.2410951"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Li G, Xu Y, Gao Q, Guo S, Zu Y, Wang X, Wang C, Zhang C and Liu D (2022). Ginsenosides restore lipid and redox homeostasis in mice with intrahepatic cholestasis through SIRT1\/AMPK pathways. Nutrients, 14(19): p.3938.","DOI":"10.3390\/nu14193938"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Li S, Ji Z, Zou M, Nie X, Shi Y and Cheng G (2011). Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine. AAPS PharmSciTech, 12(3): 1011-1018.","DOI":"10.1208\/s12249-011-9665-3"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Lu L (2022). Guidelines for the management of cholestatic liver diseases (2021). J Clin Transl Hepatol, 10(4): 757-769.","DOI":"10.14218\/JCTH.2022.00147"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"M NK, SS, P SR and Narayanasamy D (2024). The science of solid lipid nanoparticles: From fundamentals to applications. Cureus, 16(9): e68807.","DOI":"10.7759\/cureus.68807"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ma X, Zhang W, Chen Y, Hu Q, Wang Z, Jiang T, Zeng Y and Efferth T (2024). Paeoniflorin inhibited GSDMD to alleviate ANIT-induced cholestasis via pyroptosis signaling pathway. Phytomedicine, 134: 156021.","DOI":"10.1016\/j.phymed.2024.156021"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Mao L, Chen J, Cheng K, Dou Z, Leavenworth JD, Yang H, Xu D. Luo L (2022). Nrf2-dependent protective effect of paeoniflorin on \u03b1-naphthalene isothiocyanate-induced hepatic injury. Am J Chin Med., 50(5): 1331-1348.","DOI":"10.1142\/S0192415X22500562"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Muhamad Fadzil NS, Sekar M, Gan SH, Bonam SR, Wu YS, Vaijanathappa J, Ravi S, Lum PT and Dhadde SB (2021). Chemistry, pharmacology and therapeutic potential of swertiamarin - A promising natural lead for new drug discovery and development. Drug Des Devel Ther, 15: 2721-2746.","DOI":"10.2147\/DDDT.S299753"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Parihar A, Prajapati BG and Paliwal H (2025). Optimization of ivacaftor-loaded solid lipid nanoparticles for solubility enhancement. Front Pharmacol, 16: 1619481.","DOI":"10.3389\/fphar.2025.1619481"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ramirez-Cortes F and Menova P (2025). Hepatocyte targeting via the asialoglycoprotein receptor. RSC Med Chem, 16(2): 525-544.","DOI":"10.1039\/D4MD00652F"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rao H, Rao I, Ahmad S, Madni A and Ahmad I (2024). Compritol(\u00ae)-based solid lipid nanoparticles of desvenlafaxine prepared by ultrasonication-assisted hot-melt encapsulation to modify its release. Nanomedicine (Lond), 19(11): 965-978.","DOI":"10.2217\/nnm-2023-0229"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Refat M, Zhang G, Ahmed ASA, Baldi S, Zheng F and Wu X (2023). 7, 8-Dihydroxy-4-methyl coumarin alleviates cholestasis via activation of the Farnesoid X receptor in-vitro and in-vivo. Chem Biol Interact, 370: 110331.","DOI":"10.1016\/j.cbi.2022.110331"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rehman M, Tahir N, Sohail MF, Qadri MU, Duarte SOD, Brand\u00e3o P, Esteves T, Javed I and Fonte P (2024). Lipid-based nanoformulations for drug delivery: An ongoing perspective. Pharmaceutics, 16(11): 1376.","DOI":"10.3390\/pharmaceutics16111376"},{"key":"ref14","unstructured":"Sarhadi S, Gholizadeh M, Moghadasian T and Golmohammadzadeh S (2020). Moisturizing effects of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) using deionized and magnetized water by in-vivo and in-vitro methods. Iran J Basic Med Sci, 23(3): 337-343."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Shi M, Tang J, Zhang T and Han H (2022). Swertiamarin, an active iridoid glycoside from Swertia pseudochinensis H. Hara, protects against alpha-naphthylisothiocyanate-induced cholestasis by activating the farnesoid X receptor and bile acid excretion pathway. J Ethnopharmacol, 291: 115164.","DOI":"10.1016\/j.jep.2022.115164"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wang W, Zhao X, Hu H, Chen D, Gu J, Deng Y and Sun J (2010). Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability. Drug Deliv, 17(3): 114-122.","DOI":"10.3109\/10717540903580176"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wolska E. Brach M (2022). Distribution of drug substances in solid lipid microparticles (SLM)-methods of analysis and interpretation. Pharmaceutics, 14(2): p.335.","DOI":"10.3390\/pharmaceutics14020335"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zhang Q, Chen K, Wu T and Song H (2019). Swertiamarin ameliorates carbon tetrachloride-induced hepatic apoptosis via blocking the PI3K\/Akt pathway in rats. Korean J Physiol Pharmacol, 23(1): 21-28.","DOI":"10.4196\/kjpp.2019.23.1.21"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu H, Zhen W, Jiang T and Cui J (2025). Advancement of drugs conjugated with GalNAc in the targeted delivery to hepatocytes based on asialoglycoprotein receptor. Carbohydr Res, 552: 109426.","DOI":"10.1016\/j.carres.2025.109426"},{"key":"ref20","unstructured":"Wang Xiu-Mei, Bagenna and BAI Ming-gang (2007). Determination of swertiamain content in herba lomatogonii by HPLC. J. Inner Mongolia Univ. Nationalities, 22(03): 320-322."}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:02:05Z","timestamp":1788076925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":21,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.9.262.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}